Genetically modified major histocompatibility complex mice

Abstract

The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II α and β polypeptides), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.

What is claimed is: 
     
         1 . A non-human animal comprising at an endogenous Major Histocompatibility Complex II (MHC II) α gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II α polypeptide,
 wherein a human portion of the chimeric human/non-human MHC II α polypeptide comprises a human MHC II α extracellular domain, and 
 wherein the animal expresses a functional MHC II complex on a surface of a cell of the animal. 
 
     
     
         2 . The animal of  claim 1 , wherein the human MHC II α extracellular domain comprises human α1 and α2 domains. 
     
     
         3 . The animal of  claim 1 , wherein the nucleotide sequence is expressed under regulatory control of endogenous non-human MHC II α promoter and regulatory elements. 
     
     
         4 . The animal of  claim 1 , wherein a non-human portion of the chimeric human/non-human MHC II α polypeptide comprises transmembrane and cytoplasmic domains of an endogenous non-human MHC II α polypeptide. 
     
     
         5 . The animal of  claim 1 , wherein the human portion of the chimeric human/non-human MHC II α polypeptide is derived from a human HLA class II protein selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP. 
     
     
         6 . The animal of  claim 5 , wherein the human portion of the chimeric human/non-human MHC II α polypeptide is derived from a human HLA-DR4 protein. 
     
     
         7 . The animal of  claim 1 , wherein the animal is a rodent. 
     
     
         8 . The rodent of  claim 7 , wherein the rodent is a mouse. 
     
     
         9 . The animal of  claim 1 , wherein the animal further comprises at an endogenous MHC II β gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II β polypeptide. 
     
     
         10 . A non-human animal comprising at an endogenous MHC II β gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II β polypeptide,
 wherein a human portion of the chimeric human/non-human MHC II β polypeptide comprises a human MHC II β extracellular domain, and 
 wherein the animal expresses a functional MHC II complex on a surface of a cell of the animal. 
 
     
     
         11 . The animal of  claim 10 , wherein the human MHC II β extracellular domain comprises human β1 and β2 domains. 
     
     
         12 . The animal of  claim 10 , wherein the nucleotide sequence is expressed under regulatory control of endogenous non-human MHC II β promoter and regulatory elements. 
     
     
         13 . The animal of  claim 10 , wherein a non-human portion of the chimeric human/non-human MHC II β polypeptide comprises transmembrane and cytoplasmic domains of an endogenous non-human MHC II β polypeptide. 
     
     
         14 . The animal of  claim 10 , wherein the human portion of the chimeric human/non-human MHC II β polypeptide is derived from a human HLA class II protein selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP. 
     
     
         15 . The animal of  claim 14 , wherein the human portion of the chimeric human/non-human MHC II β polypeptide is derived from a human HLA-DR4 protein. 
     
     
         16 . The animal of  claim 10 , wherein the animal is a rodent. 
     
     
         17 . The rodent of  claim 16 , wherein the rodent is a mouse. 
     
     
         18 . The animal of  claim 10 , wherein the animal further comprises at an endogenous MHC II α gene locus a nucleotide sequence encoding a chimeric human/non-human MHC II α polypeptide. 
     
     
         19 . A rodent comprising at an endogenous MHC II gene locus a first nucleotide sequence encoding a chimeric human/rodent MHC II α polypeptide and a second nucleotide sequence encoding a chimeric human/rodent MHC II β polypeptide,
 wherein a human portion of the chimeric human/rodent MHC II α polypeptide comprises a human MHC II α extracellular domain and a human portion of the chimeric human/rodent MHC II β polypeptide comprises a human MHC II β extracellular domain, and 
 wherein the chimeric human/rodent MHC II α and MHC II β polypeptides form a functional MHC II complex on a surface of a cell of the rodent. 
 
     
     
         20 . The rodent of  claim 19 , wherein the human MHC II α extracellular domain comprises human α1 and α2 domains. 
     
     
         21 . The rodent of  claim 19 , wherein the human MHC II β extracellular domain comprises human β1 and β2 domains. 
     
     
         22 . The rodent of  claim 19 , wherein the first nucleotide sequence is expressed under regulatory control of endogenous rodent MHC II α promoter and regulatory elements, and the second nucleotide sequence is expressed under regulatory control of endogenous rodent MHC II β promoter and regulatory elements. 
     
     
         23 . The rodent of  claim 19 , wherein a rodent portion of the chimeric human/rodent MHC II α polypeptide comprises transmembrane and cytoplasmic domains of an endogenous rodent MHC II α polypeptide. 
     
     
         24 . The rodent of  claim 19 , wherein a rodent portion of the chimeric human/rodent MHC II β polypeptide comprises transmembrane and cytoplasmic domains of an endogenous rodent MHC II β polypeptide. 
     
     
         25 . The rodent of  claim 19 , wherein the human portions of the chimeric human/rodent MHC II α and β polypeptides are derived from a human HLA class II protein selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP. 
     
     
         26 . The rodent of  claim 25 , wherein the human portions of the chimeric human/rodent MHC II α and β polypeptides are derived from a human HLA-DR4 protein. 
     
     
         27 . The rodent of  claim 19 , wherein the rodent is a mouse. 
     
     
         28 . The mouse of  claim 27 , wherein rodent portions of the chimeric MHC II α and β polypeptides are derived from a mouse H-2E protein. 
     
     
         29 . The rodent of  claim 19 , wherein the rodent does not express functional endogenous MHC II polypeptides from their endogenous rodent MHC II loci. 
     
     
         30 . A mouse comprising at an endogenous mouse MHC II locus a first nucleotide sequence encoding a chimeric human/mouse MHC II α polypeptide and a second nucleotide sequence encoding a chimeric human/mouse MHC II β polypeptide,
 wherein a human portion of the chimeric MHC II α polypeptide comprises an extracellular domain derived from an α polypeptide of a human HLA-DR4 protein and the human portion of the chimeric MHC II β polypeptide comprises an extracellular domain derived from a β polypeptide of a human HLA-DR4 protein, 
 wherein a mouse portion of the chimeric MHC II α polypeptide comprises transmembrane and cytoplasmic domains of a mouse H-2E α chain and a mouse portion of the chimeric MHC II β polypeptide comprises transmembrane and cytoplasmic domains of a mouse H-2E β chain, 
 and wherein the mouse expresses a functional chimeric HLA-DR4/H-2E MHC II complex on a surface of a cell of the mouse. 
 
     
     
         31 . The mouse of  claim 30 , wherein the extracellular domain of the α polypeptide comprises human α1 and α2 domains. 
     
     
         32 . The mouse of  claim 30 , wherein the extracellular domain of the β polypeptide comprises human β1 and β2 domains. 
     
     
         33 . The mouse of  claim 30 , wherein the first nucleotide sequence is expressed under regulatory control of endogenous mouse MHC II α promoter and regulatory elements, and the second nucleotide sequence is expressed under regulatory control of endogenous mouse MHC II β promoter and regulatory elements. 
     
     
         34 . The mouse of  claim 30 , wherein the mouse does not express functional endogenous MHC II polypeptides from their endogenous mouse loci. 
     
     
         35 . A method of modifying an MHC II locus of a mouse to express a chimeric human/mouse MHC II complex comprising replacing at the endogenous mouse MHC II locus a nucleotide sequence encoding a mouse MHC II complex with a nucleotide sequence encoding a chimeric human/mouse MHC II complex. 
     
     
         36 . The method of  claim 35 , wherein the nucleotide sequence encoding the chimeric human/mouse MHC II complex comprises a first nucleotide sequence encoding an extracellular domain of a human MHC II α polypeptide and a transmembrane and cytoplasmic domains of a mouse MHC II α polypeptide and a second nucleotide sequence encoding an extracellular domain of a human MHC II β polypeptide and transmembrane and cytoplasmic domains of a mouse MHC II β polypeptide. 
     
     
         37 . The method of  claim 35 , wherein a human portion of the chimeric MHC II complex is derived from a human HLA class II protein selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP. 
     
     
         38 . The method of  claim 35 , wherein a mouse portion of the chimeric MHC II complex is derived from a mouse H-2E protein, and a human portion of the chimeric MHC II complex is derived from a human HLA-DR4 protein. 
     
     
         39 . The method of  claim 36 , wherein human portions of chimeric MHC II α and β polypeptides are derived a human HLA class II protein selected from the group consisting of HLA-DR, HLA-DQ, and HLA-DP. 
     
     
         40 . The method of  claim 36 , wherein mouse portions of chimeric MHC II α and β polypeptides are derived from a mouse H-2E protein, and human portions of chimeric MHC II α and β polypeptides are derived from a human HLA-DR4 protein. 
     
     
         41 . The method of  claim 35 , wherein the replacement is made in a single ES cell, and the single ES cell is introduced into a mouse embryo to make a mouse.